ADVANCED PROTEOME THERAP. Share · CA0076282098 · A2PJ6N (XTSX) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of ADVANCED PROTEOME THERAP.
No Price
Company Profile for ADVANCED PROTEOME THERAP. Share
Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company in the United States. The company develops and commercializes a platform for the chemical modification of protein therapeutics. Its platform is dedicated to applications in the field of antibody drug conjugates, as well as focused on protein conjugates and immunomodulation. The company is headquartered in Burnaby, Canada.
Company Data
Name ADVANCED PROTEOME THERAP.
Company Advanced Proteome Therapeutics Corporation
Website
https://www.advancedproteome.com
Primary Exchange 
TSX-V
TSX-V
WKN A2PJ6N
ISIN CA0076282098
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Benjamin Krantz
Country Canada
Currency EUR
Employees -
Address 8337 Eastlake Drive, V5A 4W2 Burnaby
IPO Date 2009-07-10
Stock Splits
| Date | Split |
|---|---|
| 08.05.2019 | 1:10 |
Ticker Symbols
| Name | Symbol |
|---|---|
| Over The Counter | APTCF |
More Shares
Investors who hold ADVANCED PROTEOME THERAP. also have the following shares in their portfolio:
